AAminove
Back to library

Retatrutide

Human RCT

Also known as: LY3437943

GLP-1 / incretinWeight management (investigational)Type 2 diabetes (investigational)

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

An investigational triple agonist (GIP/GLP-1/glucagon) with striking weight-loss results in phase 2 trials. Not yet approved; long-term safety is still being established.

Mechanism

Simultaneously activates GIP, GLP-1 and glucagon receptors to reduce appetite and increase energy expenditure.

Evidence

Human RCTWhat does this mean?

Phase 2 RCT data are strong for weight loss, but it is investigational and not approved; phase 3 and long-term safety are pending.

Community-reported information

Investigational and unapproved outside trials. No community schedule is presented.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~6 days (once-weekly dosing in trials).

Storage

Refrigerate per trial protocols.

Commonly reported side effects

  • Nausea
  • Diarrhoea
  • Vomiting
  • Decreased appetite

Legal status by region

  • USInvestigational; not FDA-approved. Available only in trials.
  • GBNot licensed; investigational.

Legal status changes over time; verify locally before relying on this.

Citations